These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34428735)

  • 21. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
    Weisberg E; Choi HG; Ray A; Barrett R; Zhang J; Sim T; Zhou W; Seeliger M; Cameron M; Azam M; Fletcher JA; Debiec-Rychter M; Mayeda M; Moreno D; Kung AL; Janne PA; Khosravi-Far R; Melo JV; Manley PW; Adamia S; Wu C; Gray N; Griffin JD
    Blood; 2010 May; 115(21):4206-16. PubMed ID: 20299508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
    Smith CC; Zhang C; Lin KC; Lasater EA; Zhang Y; Massi E; Damon LE; Pendleton M; Bashir A; Sebra R; Perl A; Kasarskis A; Shellooe R; Tsang G; Carias H; Powell B; Burton EA; Matusow B; Zhang J; Spevak W; Ibrahim PN; Le MH; Hsu HH; Habets G; West BL; Bollag G; Shah NP
    Cancer Discov; 2015 Jun; 5(6):668-79. PubMed ID: 25847190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
    Ai X; Sun Y; Wang H; Lu S
    Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of human Fyn kinase domain complexed with staurosporine.
    Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
    Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential.
    Prade L; Engh RA; Girod A; Kinzel V; Huber R; Bossemeyer D
    Structure; 1997 Dec; 5(12):1627-37. PubMed ID: 9438863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.
    Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH
    J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noncovalent wild-type-sparing inhibitors of EGFR T790M.
    Lee HJ; Schaefer G; Heffron TP; Shao L; Ye X; Sideris S; Malek S; Chan E; Merchant M; La H; Ubhayakar S; Yauch RL; Pirazzoli V; Politi K; Settleman J
    Cancer Discov; 2013 Feb; 3(2):168-81. PubMed ID: 23229345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gatekeeper tyrosine phosphorylation is autoinhibitory for Symbiosis Receptor Kinase.
    Paul A; Samaddar S; Bhattacharya A; Banerjee A; Das A; Chakrabarti S; DasGupta M
    FEBS Lett; 2014 Aug; 588(17):2881-9. PubMed ID: 24996184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structures of the S6K1 kinase domain in complexes with inhibitors.
    Niwa H; Mikuni J; Sasaki S; Tomabechi Y; Honda K; Ikeda M; Ohsawa N; Wakiyama M; Handa N; Shirouzu M; Honma T; Tanaka A; Yokoyama S
    J Struct Funct Genomics; 2014 Sep; 15(3):153-64. PubMed ID: 25078151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.
    Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P
    Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-receptor cytosolic protein tyrosine kinases from various rat tissues.
    Elberg G; Li J; Leibovitch A; Shechter Y
    Biochim Biophys Acta; 1995 Nov; 1269(3):299-306. PubMed ID: 7495884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.
    Shomin CD; Meyer SC; Ghosh I
    Bioorg Med Chem; 2009 Sep; 17(17):6196-202. PubMed ID: 19674907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.
    Meggio F; Donella Deana A; Ruzzene M; Brunati AM; Cesaro L; Guerra B; Meyer T; Mett H; Fabbro D; Furet P
    Eur J Biochem; 1995 Nov; 234(1):317-22. PubMed ID: 8529658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
    Fischer JJ; Dalhoff C; Schrey AK; Graebner OY; Michaelis S; Andrich K; Glinski M; Kroll F; Sefkow M; Dreger M; Koester H
    J Proteomics; 2011 Dec; 75(1):160-8. PubMed ID: 21664307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
    Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
    ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein tyrosine kinases: structure, substrate specificity, and drug discovery.
    al-Obeidi FA; Wu JJ; Lam KS
    Biopolymers; 1998; 47(3):197-223. PubMed ID: 9817025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformationally constrained peptides as protein tyrosine kinase inhibitors.
    Tiwari RK; Parang K
    Curr Pharm Des; 2012; 18(20):2852-66. PubMed ID: 22571654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staurosporine-based binding assay for testing the affinity of compounds to protein kinases.
    Iyer GH; Taslimi P; Pazhanisamy S
    Anal Biochem; 2008 Feb; 373(2):197-206. PubMed ID: 18047825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.